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Abstract
Background: The aim of the study was to evaluate self-assessed bowel toxicity after radiotherapy
(RT) for prostate cancer. In contrast to rectal bleeding, information concerning irritative symptoms
(rectal urgency, pain) and incontinence after RT has not been adequately documented and reported
in the past.
Methods: Patients (n = 286) have been surveyed prospectively before (A), at the last day (70.2-
72.0 Gy; B), a median time of two (C) and 16 months after RT (D) using a validated questionnaire
(Expanded Prostate Cancer Index Composite). Bowel domain score changes were analyzed and
patient-/dose-volume-related factors tested for a predictive value on three separate factors
(subscales): irritative symptoms, incontinence and rectal bleeding.
Results: Irritative symptoms were most strongly affected in the acute phase, but the scores of all
subscales remained slightly lower at time D in comparison to baseline scores. Good correlations
(correlation indices >0.4; p < 0.001 for all) were found between irritative and incontinence
function/bother scores at times B-D, suggesting the presence of an urge incontinence for the
majority of patients who reported uncontrolled leakage of stool. Planning target volume (PTV),
haemorrhoids and stroke in past history were found to be independent predictive factors for rectal
bleeding at time D. Chronic renal failure predisposed for lower irritative scores at time D.
Paradoxically, patients with greater rectum volumes inside higher isodose levels presented with
higher quality of life scores in the irritative and incontinence subscales.
Conclusion: PTV and specific comorbidities are important predictive factors on adverse bowel
quality of life changes after RT for prostate cancer. However, greater rectum volumes inside high
isodose levels have not been found to be associated with lower quality of life scores.
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External beam radiation is a well established curative
treatment for prostate cancer. As demonstrated in rand-
omized trials, higher doses may improve local control in
a subset of these patients [1-3]. Gastrointestinal toxicity is
known to be the dose-limiting toxicity [4]. Numerous
reports already exist in the literature [5-16].
The standard for measures of toxicity consists of RTOG/
EORTC or CTC morbidity scoring criteria, physician-
based scoring systems that assign a toxicity grade based on
symptoms reported by the patient [17-22]. Usually, a
grading is reported without the actual symptoms [1,3,23-
25]. In most cases, higher grades ≥ grade 2 indicate rectal
bleeding. In a study by Goldner et al[8], 52 (in a total
group of 166) patients were reported with grade 2-3
EORTC/RTOG late rectal side effects - the reason was rec-
tal bleeding for 50 patients (96%). A recently published
factor analysis of the EPIC (Expanded Prostate Cancer
Index Composite) questionnaire revealed three separate
factors within the bowel domain: bleeding, incontinence
and irritative symptoms [26]. The information concerning
irritative symptoms (rectal urgency, pain) and inconti-
nence is not adequately documented and reported. A
potential underestimation of symptoms results from lack
of patient reporting. Quality of life questionnaires are
used to compensate these problems. The EPIC was found
to be more sensitive to changes in bowel toxicity through
a course of radiotherapy and correlate well with RTOG/
EORTC scores [27].
The aim of this study was to evaluate gastrointestinal qual-
ity of life changes after external beam radiotherapy for
prostate cancer with discrimination of the factors concern-
ing rectal bleeding, bowel incontinence and irritative
symptoms. Patient-related and dose-volume-related fac-
tors were tested for a predictive value, respectively.
Methods
This study was based on consecutive patients who were
treated due to T1-3N0M0 prostatic carcinoma with three-
dimensional conformal radiotherapy (3DCRT) in the
years 2003-2006. The treatment was based on a treatment
planning CT scan in supine position with a slice thickness
of 5 mm. Patients were asked to have a full bladder for the
planning computed tomography (CT) scan and each radi-
otherapy fraction. In all scans prostate volume, planning
target volume (PTV), bladder and rectum were delineated
by identifying the external contours. The rectum volume
enclosed the region from the anal canal (including the
anal canal) to the rectosigmoid flexure. The integral dose
(AUC-area under the curve) was defined as the relation of
the area under the dose-volume histogram curve to the
total area, multiplied by 100. Treatment plans were calcu-
lated using a four-field box technique with 15 MeV pho-
tons and a multileaf collimator. The PTV was required to
be enclosed by the 90% isodose relative to the ICRU refer-
ence point [28] with a margin of 1.5 cm in the anterior/
lateral and 1 cm in the craniocaudal and dorsal directions
to the CTV (prostate with or without seminal vesicles).
The total dose to the prostate in the reference point was
70.2-72 Gy at 1.8-2.0 Gy daily fractions.
Patients have been surveyed prospectively before (time
A), at the last day (B), two months (median, range 6
weeks-6 months) after (C) and sixteen months (median,
range 12-20 months) after (D) radiotherapy using a vali-
dated questionnaire, the Expanded Prostate Cancer Index
Composite (EPIC) [29]. Only patients with questionnaire
results from both time A and time D have been included
in the analysis, resulting in 286 (A), 200 (B), 252 (C) and
286 (D) questionnaires at the respective points in time.
Nearly all patients who were addressed to respond before
treatment agreed to take part in the evaluation (>98%).
The response rate to the last questionnaire was 91%, so
that 28 patients who responded before treatment were
excluded from the analysis. Baseline patient characteris-
tics are presented in Table 1.
The bowel domain consists of 14 questions for function
and the subjective assessment of the associated bother
("no problem" - "very small problem" - "little problem" -
"moderate problem" - "big problem"). Questions were
classified into irritative, incontinence and bleeding sub-
scales. The multi-item scale scores were transformed line-
ary to a 0-100 scale, with higher scores representing better
health-related quality of life.
The questionnaire was handed over to the patients per-
sonally by one of the physicians at time A, B and C.
Number of questionnaires was the lowest at the end of
radiotherapy (time B) because this point in time was lim-
ited to a single day (last radiotherapy fraction) and no sec-
ond opportunity existed for a missed questionnaire.
Patients presented in the department six to ten weeks after
the end of treatment. Missed questionnaires in the acute
phase (time C) and questionnaires one to two years after
radiotherapy (time D) were sent to the patients with a
return envelope. If a questionnaire was not returned
within 4 weeks, patients were contacted by telephone and
urged to complete it.
Statistical analysis was performed using the SPSS 14.0
(SPSS, Chicago, Ill), software. To explore statistical
HRQOL score differences between different subgroups,
the Mann-Whitney-U-test was used. The Wilcoxon's
matched-pairs test was applied to determine longitudinal
changes in specific subgroups of patients, the Friedman
test to consider multiple comparisons. Contingency table
analysis with the chi-square test was performed to com-Page 2 of 10
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bles. The Spearman correlation coefficient was used to test
the correlation between two variables. In a forward step-
wise logistic multivariate analysis, different risk factors
were tested for their independence. Tested patient-related
variables were the comorbidities (see Table 1) and a neo-
adjuvant hormonal therapy, dose-volume related varia-
bles were the PTV, rectum volume and the dose to the
rectum. The dose to the rectum was described by the AUC
and an additional significant dose level. Cut-off values
were defined as parameters with the lowest p-value for dif-
ferentiation between quality of life changes (volumes
tested in 10 cm3 intervals, relative doses in 5% intervals).
All p-values reported are two-sided, p < 0.05 is considered
significant.
Results
Quality of life scores before radiotherapy and at different
intervals after radiotherapy - with differentiation of irrita-
tive symptoms, incontinence and bleeding - are presented
in Table 2. In the acute phase, irritative symptom sub-
domains were most strongly affected. Mean differences
≥10 points in comparison to baseline levels were also
reported in incontinence subdomains. Though mean dif-
ferences for bleeding remained <5 points at all intervals,
they decreased statistically significantly. Depending on
the symptom, 3-7% more patients reported their bowel
symptoms to be a moderate/great problem in comparison
to the portion before radiotherapy. While the largest dif-
ferences (7%) concerned rectal urgency and increased fre-
quency of bowel movements, the smallest differences
(and the smallest percentage at time D) were found for
bloody stools (Table 3).
Table 1: Baseline patient characteristics
patient age (years); median (range) 71 (45-84)
planning target volume (cm3); median (range) 336 (169-631)
PSA (ng/ml); median (range)
≤10 ng/ml; n (%)
8 (1.2-150)
178 (62)
biopsy Gleason score <7; n (%) 185 (65)
clinical T-stage ≤2a; n (%) 237 (83)
low risk (PSA≤10 ng/ml; Gleason score <7; clinical T-stage ≤2a); n (%) 106 (37)
intermediate risk (PSA 10-20 ng/ml or Gleason score = 7 or clinical T-stage 2b-c); n (%) 101 (35)
high risk (two risk factors or PSA>20 ng/ml or Gleason score >7 or clinical T-stage >2c); n (%) 79 (28)
neoadjuvant hormonal therapy; n (%) 90 (32)
any documented comorbidity;; n (%) 179 (63)
hypertension; n (%) 74 (26)
coronary heart disease; n (%) 76 (27)
diabetes; n (%) 34 (12)
chronic obstructive pulmonary disease; n (%) 31 (11)
haemorrhoids; n (%) 17 (6)
stroke in past history; n (%) 12 (4)
peripheral arterial disease; n (%) 10 (4)
chronic renal failure; n (%) 8 (3)Page 3 of 10
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>0.4; p < 0.001 for all) were found between irritative and
incontinence function/bother scores at times B-D, sug-
gesting the presence of an urge incontinence for the
majority of patients who reported to have symptoms of
fecal incontinence (patients with vs. without rectal
urgency ≥once a day reported uncontrolled leakage of
stool ≥once a day in 20% vs. 1% at time D; p < 0.001).
Correlation indices between irritative and rectal bleeding
scores were found to be lower (Spearman correlation coef-
ficients 0.25 and 0.30; p < 0.001 for all).
Dose-volume related and patient-related (comorbidities,
neoadjuvant hormonal therapy) factors have a significant
impact on quality of life score changes (Table 4). The
dose-volume histogram reveals a paradoxic association
with quality of life changes. Patients with a larger AUC-R,
and specifically larger volumes within higher isodose lev-
els (R70, relative rectum volume enclosed by the 70%
isodose presented in Table 4; comparable results were
found for cut-off values at 22%/25%/30% of the rectal
volume within the 90%/80%/60%-isodose) reported
smaller quality of life changes - irritative and incontinence
subdomains were both found to be affected. However, in
contrast to patients with a smaller PTV (mean difference:
0 points), patients with a larger PTV presented with lower
rectal bleeding scores more than one year after treatment
relative to baseline levels. Patients with a chronic renal
failure were found to have significantly lower irritative
scores in the chronic phase after RT. Haemorrhoids and
stroke in past history were important predictors for rectal
bleeding at time D.
Haemorrhoids (and other parameters) have not been
found to be predictive for rectal bleeding at time A. How-
ever, the factors haemorrhoids and NHT (neoadjuvant
hormonal therapy) had an independent impact on greater
irritative symptoms before RT in multivariate analysis
(Table 5). Haemorrhoids clearly increased the probability
to have a big/moderate problem with bowel habits over-
all. This increased risk remained detectable at all intervals
after RT. As already presented in Table 4, actually greater
quality of life changes after RT have not been found in the
function/bother scores or the irritative function/bother
subscores for patients with haemorrhoids.
Without an influence already before RT, the multivariate
analysis supports the independent influence of larger vol-
umes within higher isodose levels (paradoxic effect) and
chronic renal failure on late irritative symptoms; and a
larger PTV, larger volumes within higher isodose levels,
haemorrhoids and stroke in past history on rectal bleed-
ing (due to an association of NHT with PTV, the effect of
NHT has not been found to be independently predictive).
Table 2: Mean quality of life scores (quartiles in brackets) and differences in relation to baseline scores
time A mean diff.
(A-B)
time B mean diff.
(A-C)
time C mean diff.
(A-D)
time D
bowel function score 92
(89;96;100)
15 78
(68;82;93)
5 87
(79;93;96)
3 89
(86;93;100)
irritative function 89
(85;95;100)
18 72
(60;75;90)
6 85
(75;90;100)
3 87
(81;92;100)
incontinence function 97
(100;100;100)
10 88
(100;100;100)
4 93
(100;100;100)
4 93
(100;100;100)
rectal bleeding 99
(100;100;100)
4 95
(100;100;100)
2 97
(100;100;100)
3 96
(100;100;100)
bowel bother score 93
(93;100;100)
20 74
(54;82;96)
10 83
(71;93;100)
7 86
(79;96;100)
irritative bother 92
(88;100;100)
23 69
(44;75;94)
12 80
(69;94;100)
7 84
(75;94;100)
incontinence bother 97
(100;100;100)
13 86
(100;100;100)
10 88
(100;100;100)
6 91
(100;100;100)
rectal bleeding bother 99
(100;100;100)
4 95
(100;100;100)
3 96
(100;100;100)
3 95
(100;100;100)
p < 0.01 for all comparisons relative to baseline scores at time A (Wilcoxon's matched pairs test for individual comparisons and Friedman test for 
all comparisons in a line)Page 4 of 10
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with larger rectum volumes inside specific isodoses (mean
353 vs. 284 cm3 with a R70 ≥25% vs. <25%, p < 0.001).
Not a single patient (n = 80) with a PTV <300 cm3, with-
out haemorrhoids or stroke in the past history reported to
have rectal bleeding at time D. A significant effect of the
patient age on bowel incontinence was only detectable at
time C.
Discussion
This study reports in detail bowel quality of life changes
after 3DCRT, patient-related and dose-volume-related
predisposing factors. In contrast to most other studies [1-
3,11-13,25], patients were treated with a homogeneous
dose and the same radiotherapy technique. Different dose
levels usually coincide with changing treatment margins
and radiotherapy techniques, implying possibly con-
founding variables. Patients after a radical prostatectomy,
with a different anatomic situation, have not been
included. Previous surgery can be predisposing for greater
toxicity [30]. The factors irritation, incontinence and
bleeding defined separate quality of life subscales. Usually
reported RTOG/EORTC toxicity grades do not allow this
perspective. Rectal urgency or incontinence is not consid-
ered in these studies [20].
Significant correlations have been found between acute
and late quality of life changes, particularly considering
the irritative and incontinence domains. As shown by
Heemsbergen et al. [31] recently, consequential late dam-
age (non-healing acute response progressing directly into
a late effect) is a significant independent factor in the
development of late gastrointestinal toxicity.
Rectal bleeding is usually the mostly feared toxicity and in
focus of toxicity studies. It is considered a key dose-limit-
ing end point in prostate radiotherapy [4]. In contrast to
most other reports, this study does not evaluate a cumula-
tive incidence of rectal bleeding since the end of treat-
ment. The questionnaire asks about a specific period of
four weeks. This study demonstrated that rectal bleeding
is a subordinated problem in comparison to other prob-
Table 3: Specific symptoms and associated bother
time A (%) time B (%) time C (%) time D (%)
rectal urgency ≥once a day 19 45 19* 14*
uncontrolled leakage of stool ≥once a day 3 7 4* 4*
loose or liquid stools ≥rarely 53 75 58* 60*
bloody stools ≥rarely 5 17 9 13
painful bowel movements ≥rarely 22 46 36 30
>two daily bowel movements 10 31 18 17
crampy pain in the abdomen or rectum ≥once a day 1 15 6 5
moderate/big problem from:
rectal urgency 6 32 16 13
increased frequency of bowel movements 4 30 16 11
watery bowel movements 2 19 11 6
losing control of stools 1 12 8 5
bloody stools 0 3 2 3
abdominal/rectal pain 4 18 13 8
bowel habits overall 6 30 17 13
p < 0.01 for all comparisons relative to baseline scores at time A
*difference not significant (χ2-test) in relation to baseline percentage (time A)Page 5 of 10
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phase (time B and C), irritative symptoms (urgency, fre-
quency, pain) play the major role.
Incontinence was shown to be strongly associated with
irritative symptoms. Nearly without exception, a daily
incontinence was only reported with a simultaneously
present rectal urgency at time D. Anorectal manometry
pressures have not been documented in this patient pop-
ulation. Yeoh et al[32] reported significantly reduced
anorectal manometry pressures 4 to 6 weeks after radio-
therapy for patients with fecal incontinence. However,
patients with incontinence were found to have normal
basal and squeeze pressures one year after radiotherapy
[33]. In a recently published study concerning anorectal
function after radiotherapy for prostate cancer, a progres-
sive deterioration of anorectal motor and sensory func-
tion has been shown. Rectal compliance progressively
decreased and fecal sensitivity to distension increased
after treatment [34].
These results focused on a median period of 16 months
after treatment. Chronic effects several years after treat-
ment might have additional effects on quality of life. In
contrast to rectal bleeding, the cumulative incidence of
fecal incontinence has been shown to increase even after
more than five years [35]. The percentage of patients with
fecal incontinence has been shown to be higher than the
incidence of rectal bleeding requiring laser or transfusion
in the Dutch dose-escalation trial in both treatment arms
(68 Gy and 78 Gy total doses) [35], confirming the find-
ings of our study.
Significant predisposing factors for both rectal bleeding
subscale score changes and the symptom "rectal bleeding"
in multivariate analysis were the PTV, haemorrhoids and
stroke in the past history. A volume-effect is already very
well known [9,10,36]. Patients with a stroke in the past
history always take anticoagulative drugs - this is the most
probable reason for the considerably increased tendency
for bleeding. Other agents (clopidrogel/ticlopidine) or a
Table 4: Impact of patient-related and dose-volume-related factors on quality of life score changes
factor mean diff.
(A-B)
mean diff.
(A-C)
mean diff.
(A-D)
bowel function score AUC-R≥50% 13 vs. 16 3 vs. 8 1 vs. 4†
R70≥25% 15 vs. 16 4 vs. 12* 2 vs. 8*
coronary heart disease 17 vs. 14 8 vs. 4† 3 vs. 3
stroke in past history 10 vs. 15 3 vs. 5 7 vs. 3†
chronic renal failure 30 vs. 15 15 vs. 5 11 vs. 3†
irritative function AUC-R≥50% 16 vs. 20 4 vs. 8 1 vs. 5†
R70≥25% 18 vs. 18 5 vs. 13† 2 vs. 9†
chronic renal failure 41 vs. 18 8 vs. 6 12 vs. 3†
incontinence function AUC-R≥50% 11 vs. 8 0 vs. 8† 2 vs. 6
R70≥25% 10 vs. 8 3 vs. 12† 3 vs. 9†
rectal bleeding PTV≥300 cm3 4 vs. 4 2 vs. 2 4 vs. 0*
NHT 4 vs. 4 3 vs. 2 0 vs. 4*
coronary heart disease 6 vs. 3 5 vs. 1† 4 vs. 2
haemorrhoids 12 vs. 4 7 vs. 2† 9 vs. 3†
stroke in past history 0 vs. 4 0 vs. 2 10 vs. 3*
bowel bother score R70≥25% 19 vs. 27 8 vs. 22* 5 vs. 15*
stroke in past history 9 vs. 20† 2 vs. 10 8 vs. 7
chronic renal failure 37 vs. 19 11 vs. 10 21 vs. 6*
irritative bother AUC-R≥50% 10 vs.15† 8 vs. 11 6 vs. 7
R70≥25% 22 vs. 31 10 vs. 26* 6 vs.16
chronic renal failure 48 vs. 23 15 vs. 12 22 vs. 7*
incontinence bother R70≥25% 11 vs. 21 9 vs. 16 5 vs. 14†
rectal bleeding bother PTV≥300 cm3 4 vs. 6 2 vs. 4 5 vs. 0†
coronary heart disease 7 vs. 3 5 vs. 2* 3 vs. 4
only factors with significant impact on quality of life changes shown (actually significant differences marked with † p < 0.05 or *p < 0.01)Page 6 of 10
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Table 5: Impact of patient-related and dose-volume-related factors on symptoms/problems in multivariate analysis
factor time A time B time C time D
HR [95%CI]/p-value/incidence with presence vs. absence of factor
painful bowel movements ≥rarely R70≥25% - - - 0.4 [0.2-0.9]
p = 0.03
27% vs. 45%
haemorrhoids 4.5 [1.6-12]
p < 0.01
53% vs. 20%
6.3 [1.3-30]
p = 0.02
77% vs. 43%
2.7 [1.0-7.4]
p = 0.05
59% vs. 34%
-
chronic renal failure - - - 7.2 [1.4-36]
p = 0.02
75% vs. 29%
bloody stools ≥rarely PTV≥300 cm3 - - - 8.2 [2.4-28]
p < 0.01
17% vs. 4%
R70≥25% - - - 0.2 [0.1-0.6]
p < 0.01
11% vs. 23%
haemorrhoids - - 3.5 [1.0-12]
p < 0.05
24% vs. 8%
4.0 [1.2-13]
p = 0.02
29% vs. 12%
stroke in past history - - - 7.2 [2.0-26]
p < 0.01
42% vs. 12%
moderate/big problem from:
bowel habits overall R70≥25% - 0.4 [0.2-0.9]
p = 0.03
26% vs. 52%
0.4 [0.2-1.0]
p < 0.05
15% vs. 32%
-
haemorrhoids 8.1 [2.5-26]
p < 0.01
29% vs. 5%
3.4 [1.0-11]
p < 0.05
62% vs. 28%
5.9 [2.1-17]
p < 0.01
53% vs. 15%
3.3 [1.1-10]
p = 0.04
29% vs. 12%
chronic renal failure - - - 7.9 [1.9-33]
p < 0.01
50% vs. 12%
rectal urgency R70≥25% - - 0.3 [0.1-0.6]
p < 0.01
13% vs. 35%
-
NHT 4.3 [1.5-12]
p < 0.01
11% vs. 3%
- - -
haemorrhoids 5.2 [1.5-12]
p = 0.03
18% vs. 5%
3.7 [1.2-12]
p = 0.03
62% vs. 30%
- 3.4 [1.1-10]
p = 0.03
29% vs. 12%
chronic renal failure - - - 4.9 [1.1-22]
p = 0.04
28% vs. 12%
losing control of stools age≥70 years - - 3.6 [1.0-12]
p < 0.05
11% vs. 3%
-
bloody stools haemorrhoids - - - 7.0 [1.2-39]
p = 0.03
12% vs. 2%
Radiation Oncology 2009, 4:36 http://www.ro-journal.com/content/4/1/36higher aspirin dose is used in comparison with patients
with coronary artery disease of peripheral artery disease.
The association of anticoagulants with acute and late rec-
tal bleeding has been shown in other studies before
[37,38].
Haemorrhoids have been reported to be predictive for
acute tenesmus and rectal bleeding after 3DCRT before
[39]. Our study very well demonstrates the predisposition
for irritative symptoms already before 3DCRT, so that
quality of life changes did not differ significantly. How-
ever, the effect on rectal bleeding became only evident
after 3DCRT.
Higher volumes within higher isodose levels were associ-
ated with smaller quality of life changes in the irritative
and incontinence subscales after 3DCRT. The multivariate
analysis demonstrates the independence concerning irri-
tative symptoms. This result may be associated with the
specific dose constellation and treatment technique in our
patient group. Yeoh et al[34] reported a significantly
lower incidence of rectal urgency for patients after 2DCRT
vs. 3DCRT in spite of a considerably larger PTV - these
patients have likewise been treated with a four-field tech-
nique and doses not exceeding 72 Gy.
The reduction of irritative symptoms (urgency, frequency,
pain) can be the consequence of a radiation effect on
peripheral nerves. In the case of all nervous tissues, a dose
of 60 Gy is associated with a less than 5% probability of
injury, but this rises steeply with increased radiation dose.
The pathogenesis involves progressive vascular degenera-
tion, fibrosis and demyelination with loss of nerve fibres.
The latency period ranges from 6 months to several years
[40]. Comparably to an earlier development of erectile
dysfunction [41], also usually considered as a chronic
effect, differences have already been detected a few weeks
after 3DCRT. Higher total doses, exceeding 72 Gy, can be
expected to be associated with an increased risk of rectal
ulcerations [35].
The association of larger rectum volumes within specific
isodose levels with a paradoxically improved quality of
life in the bowel domain was already found in a prelimi-
nary analysis of the first eighty patients [14]. This associa-
tion was also found in an independent group of patients
after permanent brachytherapy with I-125 as mono-
therapy for prostate cancer [42]. Quality of life scores have
not been correlated with dose-volume histogram parame-
ters for the rectum in the literature before. However, a val-
idation of this association by other centres is needed.
Chronic renal failure is a rare comorbidity in a population
of prostate cancer patients, with only 3% affected in our
patient population. It has not been considered as a predis-
posing factor for toxicity before. This study has shown a
dramatically increase risk of toxicity (specifically irritative
symptoms), proven to be highly significant only more
than one year after radiotherapy in spite of a low disease
incidence. Metabolic effects must be postulated as the rea-
son for this finding, but the actual mechanism is not clear
(possibly slightly higher blood levels of toxic agents). This
finding has to be taken into account in the treatment deci-
sion process for these patients.
Conclusion
Irritative symptoms constitute the major problem for
patients in the acute phase during and after external beam
radiotherapy for prostate cancer. Irritative symptoms,
incontinence and rectal bleeding are all affected in the
chronic phase. Rectal bleeding - usually estimated to be
the most worrying symptom - is bothering the patients
less in comparison to irritative symptoms and inconti-
nence. Depending on the symptom, 3-7% more patients
reported their bowel symptoms to be a moderate/great
problem in relation to baseline values before radiother-
apy. Incontinence correlates significantly with irritative
symptoms.
Planning target volume, haemorrhoids and stroke in past
history were found to be independent predictive factors
for chronic rectal bleeding. However, greater rectum vol-
umes inside high isodose levels have not been found to be
associated with lower quality of life scores.
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